Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 15, 2026 07:30 ET | Source: MiNK Therapeutics

MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation

Randomized Phase 2 trial initiated for agenT-797 in severe acute lung injury and respiratory distress, with preliminary data expected in the second half of 2026AACR and ASGCT presentations showcase...
May 14, 2026 07:30 ET | Source: MiNK Therapeutics

MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness

Randomized Phase 2 trial evaluates off-the-shelf invariant natural killer T (iNKT) cell therapy in patients with acute lung injury and hypoxemic respiratory failure Study initiates in Lviv, Ukraine,...
May 12, 2026 07:35 ET | Source: MiNK Therapeutics

MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026

iNKT therapy, agenT-797, delivers context-dependent immune reprogramming showing activation in cancer and anti-inflammatory benefit in ARDS — from the same manufacturing donor batch, without genetic...
May 08, 2026 16:30 ET | Source: MiNK Therapeutics

MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs

NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies...
April 17, 2026 15:00 ET | Source: MiNK Therapeutics

MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer

First study of agenT-797, botensilimab (BOT) and balstilimab (BAL) in gastroesophageal cancer shows disease control rate (DCR) in 77% of patients and long-term survival beyond 20 months in a subset of...
April 03, 2026 07:30 ET | Source: MiNK Therapeutics

MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026

Study will highlight novel iNKT cell-based combinations in checkpoint-refractory diseaseData expected to inform immune modulation, treatment sequencing strategy, and clinical durability of response ...
April 02, 2026 07:30 ET | Source: MiNK Therapeutics

MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy

NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell...
April 01, 2026 07:30 ET | Source: MiNK Therapeutics

MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference

NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell...
March 31, 2026 07:30 ET | Source: MiNK Therapeutics

MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum

ARDS / hypoxemic pneumonia Phase 2 trial initiation 1H 2026; early data by year end; market opportunity of ~200,000–300,000 patients annually in US/EUC-Further Consortium collaboration adds to growing...
March 17, 2026 07:30 ET | Source: MiNK Therapeutics

MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies...